/
Nephrology
Focal Segmental Glomerulosclerosis
9
Pipeline Programs↗
8
Active Trials↗
17
Companies Involved↗
Focal Segmental Glomerulosclerosis is an early-stage landscape with 9 programs across 17 companies. The most active players are Sanofi, Apellis Pharmaceuticals, Travere Therapeutics, Inc.. 1 program is in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 1
No programs
Phase 25
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
8 of 9 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.
Analysis
Trial Status
42
clinical trials
Completed23 · 55%
Terminated7 · 17%
Recruiting6 · 14%
Active, not recruiting2 · 5%
Withdrawn2 · 5%
Unknown status2 · 5%
Clinical Trials
Trial Activity
42 trials
Genetic Markers for Focal Segmental Glomerulosclerosis
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00001393·616 enrolled
Pirfenidone to Treat Kidney Disease (Focal Segmental Glomerulosclerosis)
Completed·National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001959·21 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)